No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PNTGThe Pennant Group, Inc. | 1.03B | 29.90 | 42.11 | 27.59% | 3.15% | 7.78% | 2.93% | 0.88 |
| CHEChemed Corporation | 6.48B | 458.93 | 23.07 | 7.37% | 11.02% | 25.89% | 5.68% | 0.13 |
| EHABEnhabit, Inc. | 551.11M | 10.89 | -3.50 | -1.1% | -1.14% | -1.99% | 8.6% | 1.03 |
| AVAHAveanna Healthcare Holdings Inc. | 2.04B | 9.76 | -172.13 | 6.82% | 0.85% | 1.29% |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 1.08B | 1.11B | 1.07B | 1.05B | 1.03B |
| Revenue Growth % | - | 0.03% | -0.03% | -0.02% | -0.01% |
| Cost of Goods Sold | 537.5M | 513.9M | 525.6M | 535.6M | 530.8M |
| COGS % of Revenue | 0.5% | 0.46% | 0.49% | 0.51% | 0.51% |
| Gross Profit | 540.7M | 592.7M | 545.5M | 510.7M | 504M |
| Gross Margin % | 0.5% | 0.54% | 0.51% | 0.49% | 0.49% |
| Gross Profit Growth % | - | 0.1% | -0.08% | -0.06% | -0.01% |
| Operating Expenses | 438M | 449.8M | 556.9M | 558.3M | 619.1M |
| OpEx % of Revenue | 0.41% | 0.41% | 0.52% | 0.53% | 0.6% |
| Selling, General & Admin | 398M | 412.9M | 414.9M | 441.6M | 425.9M |
| SG&A % of Revenue | 0.37% | 0.37% | 0.39% | 0.42% | 0.41% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 40M | 36.9M | 142M | 116.7M | 193.2M |
| Operating Income | 102.7M | 142.9M | -11.4M | -47.6M | -115.1M |
| Operating Margin % | 0.1% | 0.13% | -0.01% | -0.05% | -0.11% |
| Operating Income Growth % | - | 0.39% | -1.08% | -3.18% | -1.42% |
| EBITDA | 142.7M | 179.8M | 21.6M | -16.7M | -83.6M |
| EBITDA Margin % | 0.13% | 0.16% | 0.02% | -0.02% | -0.08% |
| EBITDA Growth % | - | 0.26% | -0.88% | -1.77% | -4.01% |
| D&A (Non-Cash Add-back) | 40M | 36.9M | 33M | 30.9M | 31.5M |
| EBIT | 105.4M | 148.3M | -10.5M | -47.4M | -115.1M |
| Net Interest Income | -5.2M | -300K | -15M | -43M | -42.9M |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.2M | 300K | 15M | 43M | 42.9M |
| Other Income/Expense | -2.5M | 5.1M | -14.1M | -42.8M | -42.9M |
| Pretax Income | 100.2M | 148M | -25.5M | -90.4M | -158M |
| Pretax Margin % | 0.09% | 0.13% | -0.02% | -0.09% | -0.15% |
| Income Tax | 24.4M | 35.1M | 12.8M | -11.4M | -4M |
| Effective Tax Rate % | 0.75% | 0.75% | 1.58% | 0.89% | 0.99% |
| Net Income | 75M | 111.1M | -40.4M | -80.5M | -156.2M |
| Net Margin % | 0.07% | 0.1% | -0.04% | -0.08% | -0.15% |
| Net Income Growth % | - | 0.48% | -1.36% | -0.99% | -0.94% |
| Net Income (Continuing) | 75.8M | 112.9M | -38.3M | -79M | -154M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 6.7M | 13.3M | 33.6M | 32M | 30.4M |
| EPS (Diluted) | 19.23 | 28.49 | 1.25 | -1.61 | -3.11 |
| EPS Growth % | - | 0.48% | -0.96% | -2.29% | -0.93% |
| EPS (Basic) | 19.23 | 28.49 | 1.25 | -1.61 | -3.11 |
| Diluted Shares Outstanding | 3.9M | 3.9M | 50.1M | 49.9M | 50.2M |
| Basic Shares Outstanding | 3.9M | 3.9M | 50.1M | 50.05M | 50.2M |
| Dividend Payout Ratio | 1.93% | 1.39% | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 182.6M | 178.8M | 211.8M | 210.1M | 192.7M |
| Cash & Short-Term Investments | 38.5M | 5.4M | 22.9M | 27.4M | 28.4M |
| Cash Only | 38.5M | 5.4M | 22.9M | 27.4M | 28.4M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 136.5M | 164.5M | 161M | 164.7M | 149.2M |
| Days Sales Outstanding | 46.21 | 54.26 | 54.86 | 57.46 | 52.63 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 1.5M | 2.6M | 27.9M | 18M | 15.1M |
| Total Non-Current Assets | 1.43B | 1.54B | 1.31B | 1.22B | 1.03B |
| Property, Plant & Equipment | 65.1M | 68.8M | 62.4M | 76.5M | 70.5M |
| Fixed Asset Turnover | 16.56x | 16.08x | 17.17x | 13.68x | 14.68x |
| Goodwill | 1.09B | 1.19B | 1.14B | 1.06B | 900M |
| Intangible Assets | 269.4M | 259.1M | 102.6M | 80M | 58.1M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 11M | 24.3M | 5.2M | 5.3M | 4.7M |
| Total Assets | 1.62B | 1.72B | 1.53B | 1.43B | 1.23B |
| Asset Turnover | 0.67x | 0.64x | 0.70x | 0.73x | 0.84x |
| Asset Growth % | - | 0.06% | -0.11% | -0.06% | -0.14% |
| Total Current Liabilities | 126.9M | 136.5M | 132.9M | 137.7M | 126.2M |
| Accounts Payable | 3.4M | 3.5M | 3.8M | 7.6M | 6.7M |
| Days Payables Outstanding | 2.31 | 2.49 | 2.64 | 5.18 | 4.61 |
| Short-Term Debt | 6.5M | 5M | 23.1M | 22.5M | 22.8M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 34.1M | 24.8M | 40.7M | 40.7M | 36.4M |
| Current Ratio | 1.44x | 1.31x | 1.59x | 1.53x | 1.53x |
| Quick Ratio | 1.44x | 1.31x | 1.59x | 1.53x | 1.53x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 100.1M | 100.2M | 618.6M | 594.2M | 545.9M |
| Long-Term Debt | 3.2M | 3.5M | 560M | 530.1M | 492.6M |
| Capital Lease Obligations | 27.3M | 33.5M | 28.1M | 45.7M | 41.8M |
| Deferred Tax Liabilities | 54.7M | 63.2M | 28.6M | 17.1M | 11.5M |
| Other Non-Current Liabilities | 14.9M | 0 | 1.9M | 1.3M | 0 |
| Total Liabilities | 227M | 236.7M | 751.5M | 731.9M | 672.1M |
| Total Debt | 50.5M | 56.9M | 625.2M | 610.1M | 569.5M |
| Net Debt | 12M | 51.5M | 602.3M | 582.7M | 541.1M |
| Debt / Equity | 0.04x | 0.04x | 0.81x | 0.87x | 1.03x |
| Debt / EBITDA | 0.35x | 0.32x | 28.94x | - | - |
| Net Debt / EBITDA | 0.08x | 0.29x | 27.88x | - | - |
| Interest Coverage | 19.75x | 476.33x | -0.76x | -1.11x | -2.68x |
| Total Equity | 1.39B | 1.48B | 775.3M | 701.7M | 553.9M |
| Equity Growth % | - | 0.07% | -0.48% | -0.09% | -0.21% |
| Book Value per Share | 356.36 | 380.33 | 15.48 | 14.06 | 11.03 |
| Total Shareholders' Equity | 1.38B | 1.47B | 741.7M | 669.7M | 523.5M |
| Common Stock | 100K | 500K | 500K | 500K | 500K |
| Retained Earnings | 264.3M | 375.4M | 335M | 254.5M | 98.3M |
| Treasury Stock | 0 | 0 | 0 | -600K | -1.7M |
| Accumulated OCI | 0 | 0 | -700K | -500K | -200K |
| Minority Interest | 6.7M | 13.3M | 33.6M | 32M | 30.4M |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | 24.9M | 123.3M | 80.1M | 48.4M | 51.2M |
| Operating CF Margin % | 0.02% | 0.11% | 0.07% | 0.05% | 0.05% |
| Operating CF Growth % | - | 3.95% | -0.35% | -0.4% | 0.06% |
| Net Income | 75M | 112.9M | -38.3M | -80.5M | -154M |
| Depreciation & Amortization | 40M | 36.9M | 33M | 30.9M | 31.5M |
| Stock-Based Compensation | 0 | 3.6M | 9.2M | 8.9M | 11.7M |
| Deferred Taxes | 18.5M | 8.6M | -4.3M | -11.6M | -5.7M |
| Other Non-Cash Items | 3.5M | -5.9M | 109.7M | 89M | 162.6M |
| Working Capital Changes | -112.1M | -32.8M | -29.2M | 11.7M | 5.1M |
| Change in Receivables | -32.9M | -24.8M | 21.6M | -14.6M | 15.5M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -500K | -700K | 200K | 3.8M | -1M |
| Cash from Investing | -3M | -119.2M | -42.3M | -5.3M | -2.4M |
| Capital Expenditures | -3.6M | -4.3M | -7.1M | -3.5M | -3.8M |
| CapEx % of Revenue | 0% | 0% | 0.01% | 0% | 0% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 1.7M | 2.6M | 1.1M | 1M | 1.4M |
| Cash from Financing | -16.7M | -36.1M | -18.6M | -40.5M | -48.3M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | -144.5M | -154.1M | -654.9M | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | -1.3M | 125.2M | 61.3M | -7.1M | -4.7M |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | 21.7M | 119M | 73M | 44.9M | 47.4M |
| FCF Margin % | 0.02% | 0.11% | 0.07% | 0.04% | 0.05% |
| FCF Growth % | - | 4.48% | -0.39% | -0.38% | 0.06% |
| FCF per Share | 5.56 | 30.51 | 1.46 | 0.90 | 0.94 |
| FCF Conversion (FCF/Net Income) | 0.33x | 1.11x | -1.98x | -0.60x | -0.33x |
| Interest Paid | 0 | 200K | 13.1M | 0 | 0 |
| Taxes Paid | 0 | 28.4M | 11.9M | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | 5.4% | 7.73% | -3.58% | -10.9% | -24.88% |
| Return on Invested Capital (ROIC) | 5.49% | 7.3% | -0.59% | -2.68% | -7.26% |
| Gross Margin | 50.15% | 53.56% | 50.93% | 48.81% | 48.71% |
| Net Margin | 6.96% | 10.04% | -3.77% | -7.69% | -15.09% |
| Debt / Equity | 0.04x | 0.04x | 0.81x | 0.87x | 1.03x |
| Interest Coverage | 19.75x | 476.33x | -0.76x | -1.11x | -2.68x |
| FCF Conversion | 0.33x | 1.11x | -1.98x | -0.60x | -0.33x |
| Revenue Growth | - | 2.63% | -3.21% | -2.32% | -1.1% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Home Health | 877.1M | 850.1M | 824.8M |
| Home Health Growth | - | -3.08% | -2.98% |
Enhabit, Inc. (EHAB) reported $1.05B in revenue for fiscal year 2024. This represents a 3% decrease from $1.08B in 2020.
Enhabit, Inc. (EHAB) saw revenue decline by 1.1% over the past year.
Enhabit, Inc. (EHAB) reported a net loss of $11.9M for fiscal year 2024.
Enhabit, Inc. (EHAB) has a return on equity (ROE) of -24.9%. Negative ROE indicates the company is unprofitable.
Enhabit, Inc. (EHAB) generated $57.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.